The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Cell Line, 2002Establishing stable lines of human nigral dopaminergic progenitor cells
We intend to develop lines of clonal, stable and self-renewing human dopamine-producing neuronal progenitor cells. These will be derived from the part of the midbrain that gives rise to dopamine...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Development of Small Molecule Proteasome Activators for the Treatment of Parkinson's Disease
Study Rationale: Proteasomes are cylinder-like structures inside cells that breakdown unnecessary or damaged proteins. When proteasomes do not work properly, the unwanted proteins may accumulate and...
-
Seed Amplification Assay Innovation Program, 2025Detection of Alpha-synuclein Aggregates in Tear Fluid of Patients with Parkinson’s Disease
Study Rationale: Parkinson’s disease is often diagnosed using tests that require spinal fluid, which is collected through an invasive procedure called a lumbar puncture. However, this method can be...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025PINK1 Activators for Treating Parkinson's Disease
Study Rationale: Parkinson’s disease (PD) is caused by the loss of neurons in the brain due to their inability to remove damaged and dysfunctional mitochondria. PINK1 kinase located on mitochondria is...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Development of Anti-TLR2 Antibody Encapsulated with Polymer Nanoparticles Using a DNA Bar-coding Technology for Enhanced Brain Delivery
Study Rationale: Parkinson’s disease (PD) worsens over time, partly due to the spread of a harmful protein called α-synuclein between brain cells. This protein also triggers inflammation, which...
-
Seed Amplification Assay Innovation Program, 2025Blood-based Same-day Nano-QuIC for Rapid Detection of Misfolded Alpha-synuclein in Parkinson's Disease
Study Rationale: Parkinson’s disease is caused by the accumulation of misfolded alpha-synuclein, a protein that spreads in the brain and nervous system. Current cerebrospinal fluid (CSF) tests require...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.